February 11, 2013 at 08:00 AM EST
SurModics' New Low Friction, Low Particulate Device Coatings Introduced

SurModics, Inc. (Nasdaq: SRDX), a leading provider of surface modification for medical devices, today introduced SurModics Serene™ lubricious coatings for endovascular medical devices. Serene coatings are a breakthrough technology that delivers lubricity and durability while significantly reducing particulates. They are optimized for a wide range of catheter substrates and are used on FDA-cleared coronary and peripheral devices. The new coating is being introduced at the MD&M West meeting currently taking place in Anaheim, Calif.

“The Serene coating platform successfully addresses medical device manufacturers’ interest in a high-performance lubricious coating that also yields the lowest amount of particulates,” says Charlie Olson, senior vice president and general manager of SurModics’ Medical Device business.

Particulate generation during endovascular procedures is an area of interest for regulators. Several factors can contribute to particulate generation: device materials and design, device coatings, clinical technique, and the type of procedure. In recent years, manufacturers of minimally invasive medical devices have received more characterization requests from regulatory agencies seeking test results and justifications for particulate levels associated with their coated devices.

While medical device manufacturers cannot control all the variables that may result in particulate generation, SurModics Serene coatings give them the option of a lower particulate coating platform that optimizes both lubricity and durability.

“This next-generation coating is the culmination of several years of development work,” says Gary Maharaj, president and chief executive officer. “As a market leader in coatings, we will continue to create innovative products that help advance our customers’ coronary, peripheral, neuro, and structural heart devices.”

About SurModics, Inc.
SurModics’ mission is to exceed our customers’ expectations and enhance patients’ well-being by providing the world’s foremost, innovative surface modification technologies and in vitro diagnostic chemical components. SurModics partners with the world’s leading and emerging medical device, diagnostic and life science companies to develop and commercialize innovative products designed to improve patient diagnosis and treatment. Core offerings include surface modification coating technologies that impart lubricity, prohealing, and biocompatibility characteristics, and components for in vitro diagnostic test kits and microarrays. SurModics is headquartered in Eden Prairie, Minn. For more information, visit www.surmodics.com. The content of SurModics’ website is not part of this press release or part of any filings that the Company makes with the SEC.

Contacts:

SurModics, Inc.
Tim Arens, 952-500-7000
Vice President, Finance and Interim Chief Financial Officer
Related Stocks:
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here